HomeAI · summaries
Storia in 10 fonti
Novartis acquires British start-up Myricx Bio
The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Novartis to acquire ADC developer in a deal worth up to $1.5B
The deal hands over two ADCs with a different mechanism of action targeting cell growth, and marks Novartis' entry into ADC development.
- ·
afr.com
Aussie super funds hit the jackpot in $2b UK biotech deal
Brandon Capital will receive more than $300 million from the sale of Myricx, which is developing cancer-killing “biological missiles”, to Swiss giant Novartis.
- ·
morningstar.com
Correction to Novartis Article
Novartis will pay up to $400 million in potential additional payments. "Novartis to Buy Myricx Bio for Up to $1.5 Billion," at 0523 GMT, misstated the figure.
- ·
ilsole24ore.com
Novartis: rileva gruppo biotecnologie Myricx Bio per 1,1 mld $
(Il Sole 24 Ore Radiocor) - Il colosso farmaceutico svizzero Novartis ha rilevato il gruppo britannico delle biotecnologie Myricx Bio per un importo iniziale...
- ·
thenextweb.com
Novartis buys UK biotech Myricx for up to $1.5bn to chase a new cancer-drug class
Novartis will pay $1.1bn upfront and up to $400m in milestones for Myricx Bio, a UK firm developing a novel payload for antibody-drug conjugates.
- ·
techfundingnews.com
London's Myricx Bio lands up to $1.5B Novartis exit after raising just $121M — TFN
Novartis has agreed to acquire London biotech Myricx Bio for up to $1.5 billion, believing on its NMT inhibitor payload as a possible answer to ADC drug resistance.
- ·
swissinfo.ch
Novartis acquires British start-up Myricx Bio
The Swiss pharma giant will pay $1.1 billion (CHF883 million) to acquire Myricx Bio, which is developing antibody-drug conjugates for various types of solid tumours.
- ·
endpoints.news
Novartis commits $1.1B upfront to take Myricx Bio and its next-gen ADC platform
Novartis pays $1.1B upfront (up to $1.5B total) for Myricx Bio, gaining its NMT inhibitor ADC payload platform and two preclinical oncology assets.
- ·
Novartis rileva Myricx Bio in un’operazione fino a 1,5 miliardi di dollari
Da inizio anno sono state concluse 23 operazioni di M&A nel biotech per un controvalore di 94 miliardi di dollari, contro 103 miliardi del 2025
- ·
benzinga.com
Novartis Scoops up UK Biotech Myricx in $1.5 Billion Cancer Push - Novartis (NYSE:NVS)
Novartis acquires Myricx Bio for up to $1.5B to boost its oncology pipeline with a novel next-gen ADC cancer platform. Read more.
- ·
cityam.com
Patent cliff fuels Novartis' $1.5bn swoop for London biotech
Novartis has acquired UK biotech Myricx for up to $1.5bn as global drugmakers invest inpromising biotech firms ahead expected patent expiries